ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib

ArriVent BioPharma, Inc.

2025-Q1 EPS reported -$1.90

Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.
Completed enrollment in global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC EGFR exon20 insertion mutations.
Plans to provide update on firmonertinib in EGFR PACC mutant NSCLC in Q2 2025; topline Phase 3 data expected in 2025.
First IND for ARR-217 (CDH17 ADC) submitted in China; initial focus on colorectal, pancreatic, and other GI cancers.
Appointed Merdad Parsey, former Gilead CMO, to Board of Directors in April 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.